CN115605201A - 血管紧张素ii 2型受体激动剂的新用途 - Google Patents

血管紧张素ii 2型受体激动剂的新用途 Download PDF

Info

Publication number
CN115605201A
CN115605201A CN202180035480.3A CN202180035480A CN115605201A CN 115605201 A CN115605201 A CN 115605201A CN 202180035480 A CN202180035480 A CN 202180035480A CN 115605201 A CN115605201 A CN 115605201A
Authority
CN
China
Prior art keywords
respiratory
compound
use according
virus
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180035480.3A
Other languages
English (en)
Chinese (zh)
Inventor
C·J·达尔加德
J·劳德
R·巴塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vicore Pharma AB
Original Assignee
Vicore Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2004209.9A external-priority patent/GB202004209D0/en
Priority claimed from GBGB2009574.1A external-priority patent/GB202009574D0/en
Application filed by Vicore Pharma AB filed Critical Vicore Pharma AB
Publication of CN115605201A publication Critical patent/CN115605201A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180035480.3A 2020-03-23 2021-03-22 血管紧张素ii 2型受体激动剂的新用途 Pending CN115605201A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB2004209.9A GB202004209D0 (en) 2020-03-23 2020-03-23 New use
GB2004209.9 2020-03-23
GB2009574.1 2020-06-23
GBGB2009574.1A GB202009574D0 (en) 2020-06-23 2020-06-23 New use
US17/113,416 US11123329B1 (en) 2020-03-23 2020-12-07 Use of angiotensin II type 2 receptor agonist
US17/113,416 2020-12-07
PCT/GB2021/050699 WO2021191592A1 (en) 2020-03-23 2021-03-22 New use of angiotensin ii type 2 receptor agonist

Publications (1)

Publication Number Publication Date
CN115605201A true CN115605201A (zh) 2023-01-13

Family

ID=77747178

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180035480.3A Pending CN115605201A (zh) 2020-03-23 2021-03-22 血管紧张素ii 2型受体激动剂的新用途

Country Status (12)

Country Link
US (2) US11123329B1 (https=)
EP (1) EP4125881B1 (https=)
JP (1) JP7671305B2 (https=)
CN (1) CN115605201A (https=)
CA (1) CA3176108A1 (https=)
ES (1) ES2992423T3 (https=)
HR (1) HRP20241435T1 (https=)
HU (1) HUE068662T2 (https=)
PL (1) PL4125881T3 (https=)
RS (1) RS66072B1 (https=)
SM (1) SMT202400427T1 (https=)
WO (1) WO2021191592A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004094D0 (en) * 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
US20220233480A1 (en) * 2020-03-23 2022-07-28 Vicore Pharma Ab Use of angiotensin ii type 2 receptor agonist
AU2021258178A1 (en) * 2020-04-22 2022-11-17 Airway Therapeutics, Inc. Use of surfactant protein D to treat viral infections
US20240408065A1 (en) * 2021-09-30 2024-12-12 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Cyano compound, and preparation method therefor and use thereof
CN115583984A (zh) * 2022-01-11 2023-01-10 嘉兴安谛康生物科技有限公司 氮杂螺类化合物及其制备方法、药物组合物和用途
CN114948950A (zh) * 2022-01-19 2022-08-30 广州谷森制药有限公司 一种药物组合物及其抗病毒用途
WO2024153020A1 (zh) * 2023-01-16 2024-07-25 海南先声药业有限公司 抗病毒药物组合物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1529697B (zh) 2001-05-31 2010-09-22 维科尔药物公司 用作血管紧张素ⅱ激动剂的三环化合物
EP1723962A1 (en) 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
EP3265082A1 (en) 2015-03-02 2018-01-10 Vicore Pharma AB Angiotensin ii receptor agonist for treating pulmonary fibrosis
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CYNTHIA LIU等: "Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases", ACS CENT SCI., vol. 6, no. 3, 12 March 2020 (2020-03-12), pages 11 - 14, XP055724944, DOI: 10.1021/acscentsci.0c00272 *

Also Published As

Publication number Publication date
ES2992423T3 (es) 2024-12-12
JP7671305B2 (ja) 2025-05-01
US11123329B1 (en) 2021-09-21
EP4125881A1 (en) 2023-02-08
JP2023520323A (ja) 2023-05-17
US20210386712A1 (en) 2021-12-16
EP4125881C0 (en) 2024-07-24
RS66072B1 (sr) 2024-11-29
CA3176108A1 (en) 2021-09-30
SMT202400427T1 (it) 2024-11-15
HUE068662T2 (hu) 2025-01-28
PL4125881T3 (pl) 2024-12-02
US20210290596A1 (en) 2021-09-23
HRP20241435T1 (hr) 2024-12-20
WO2021191592A1 (en) 2021-09-30
EP4125881B1 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
EP4125881B1 (en) New use of angiotensin ii type 2 receptor agonist
Blair Remdesivir: A Review in COVID-19: HA Blair
JP6441888B2 (ja) 自己免疫性障害の処置におけるレボセチリジン及びモンテルカストの使用
US11052073B1 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
JP2013056947A (ja) 気管支感染症の治療法
JP2026004455A (ja) 敗血症を処置するための方法および組成物
JP2013529627A (ja) ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するｃ型肝炎ウイルス関連疾患の処置
KR20190113955A (ko) 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
WO2012104402A1 (en) Treatment of severe persitent asthma with masitinib
EP4313043A1 (en) Treatment of hidradenitis suppurativa with orismilast
US20230021647A1 (en) Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
JP2024535095A (ja) タウロデオキシコリン酸またはその薬学的に許容可能な塩および抗ウイルス剤を有効成分として含有するコロナウイルス感染症－１９（ｃｏｖｉｄ－１９）治療用組成物
TW202203934A (zh) 治療涉及全身過度發炎性反應的病症的受體相互作用蛋白激酶抑制劑
TW201204360A (en) Treatment of multiple sclerosis with MASITINIB
US20220233480A1 (en) Use of angiotensin ii type 2 receptor agonist
US11160814B1 (en) Methods of treatment for disease from coronavirus exposure
JP7840570B2 (ja) コロナウイルス感染症の処置のための方法
CN114728003B (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
KR20230054444A (ko) 호흡기 질환 치료에 사용하기 위한 (1r,3s)-3-((5-시아노-4-페닐티아졸-2-일)카바모일)사이클로펜탄-1-카르복시산 및 이의 유도체
HK40081689A (en) New use of angiotensin ii type 2 receptor agonist
HK40081689B (en) New use of angiotensin ii type 2 receptor agonist
US11471448B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
Romanelli et al. Crucial aspects of the management of solid organ transplant patient with COVID-19: a narrative review
WO2021207386A1 (en) Methods, compositions, and dosing regimens for treatment of sars-cov-2 infections
US20240082229A1 (en) Methods for preventing or treating h. pylori infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination